Spinogenix’s Fragile X Syndrome (FXS) drug is the first to show rescued well-established resting EEG abnormalities, ...
Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics that restore synapses to improve the lives of patients worldwide, today announced the publication of ...
Fragile X syndrome, an inherited cause of autism and intellectual disability, can have consequences even for carriers of the disorder who don't have full-blown symptoms. Some carriers may experience ...
The Miraglia and Cashman families of Danvers are hosting the third annual "Find a cure for Fragile X" golf tournament. Proceeds from the tournament will benefit The Fragile X Research Foundation in ...
LOS ANGELES, July 7, 2025 /PRNewswire/ -- Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics that restore synapses to improve the lives of patients ...
Mutations in FMR1, the gene encoding fragile X messenger ribonucleoprotein 1 (FMRP), located at Xq27.3 and discovered in 1991, are the leading single-gene causes of autism and intellectual disability.
Les Laboratoires Servier said that it agreed to acquire a potential treatment for Fragile X syndrome (FXS), the most common genetic cause of autism spectrum disorder (ASD), from its original developer ...
Numerous potential treatments for neurological conditions, including autism spectrum disorders, have worked well in lab mice but then disappointed in humans. What would help is a non-invasive, ...
Medicxi Ventures’ asset-focused investment model has scored another hit, in a $450 million deal with Servier SA, for KER-0193, an oral small molecule that is ready for phase II development in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results